Arrieta O, Catalán R, Guzmán-Vazquez S, et al. - In patients with non-small cell lung cancer (NSCLC) with oncogenic EGFR (epidermal growth factor receptor) mutations, researchers compared three first and second generation tyrosine-kinase inhibitors (TKIs) (afatinib, erlotinib, and gefitinib) in terms of cost-effectiveness, since the cost of these drugs is often a barrier in developing countries. They included 99 patients with NSCLC with EGFR mutations who were given these agents as first-line therapy in this retrospective cost-effectiveness analysis. In terms of overall survival (OS) and progression free survival (PFS), erlotinib, afatinib, and gefitinib showed statistically equal effectiveness as treatment options for cases with advanced EGFR-mutated NSCLC. On account of its marginally elevated PFS and OS, the cost-effectiveness analysis ascertained that afatinib afforded a slightly better cost-effective choice relative to first-generation TKIs (erlotinib and gefitinib).